title: New formulated "DOX-MTX-loaded nanoparticles" down- regulate HER2 gene expression and improve the clinical outcome in OSCCs model in rat: the effect of IV and oral modalities.
abstract: BACKGROUND
  Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. In this study, we evaluate the efficacy of our novel pH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in affecting HER2 expression profile in OSCC model in rat.
  
  
  RESULTS
  DOX-MTX- nanoparticle complexes caused significant decrease in mRNA level of HER2 compared to untreated cancers (p<0.05) and this finding was more pronounced with the IV mode (p<0.000). Surprisingly, HER2 mRNA was not affected in DOX treated as compared to the control group (p>0.05). On the other hand, in the DOX-MTX NP treated group, fewer tumors characterized with advanced stage and decreased HER2 paralleled improved clinical outcome (P<0.05). Moreover, the effectiveness of the oral route in the group treated with nanodrug accounted for the enhanced bioavailability of nanoparticulated DOX-MTX compared to free DOX. Furthermore, there was no significant difference in mRNA level of HER2 (p>0.05).
  
  
  CONCLUSIONS
  Influence of HER2 gene expression is a new feature and mechanism of action observed only in dual action DOX-MTX-NPs treated groups. Down-regulation of HER2 mRNA as a promising marker and prognosticator of OSCC adds to the cytotoxic benefits of DOX in its new formulation. Both oral and IV application of this nanodrug could be used, with no preferences in term of their safety or toxicity. As HER2 is expressed abundantly by a wide spectrum of tumors, i DOX-MTX NPs may be useful for a wide-spectrum of lesions. However, molecular mechanisms underlying HER2 down regulation induced by DOX-MTX NPs remain to be addressed.
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran E-mail : jahanbanr@tbzmed.ac.ir.
authors.forename: Mehran Mesgari
authors.initials: MM
authors.lastname: Abbasi
authors.forename: Amir
authors.initials: A
authors.lastname: Monfaredan
authors.forename: Hamed
authors.initials: H
authors.lastname: Hamishehkar
authors.forename: Rana
authors.initials: R
authors.lastname: Jahanban-Esfahlan
mesh_terms: D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics*; D016009:Chi-Square Distribution; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D016503:Drug Delivery Systems / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000187:drug effects* / Q000235:genetics; D007262:Infusions, Intravenous; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D058990:Molecular Targeted Therapy / Q000379:methods; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000235:genetics*; D053758:Nanoparticles; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D016896:Treatment Outcome
chemical_list: D012333:RNA, Messenger; D004317:Doxorubicin; D008727:Methotrexate